New biosimilar aims to offer cheaper option for colorectal cancer
NCT ID NCT07543471
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tests a new drug called HLX05-N, which is a biosimilar (a copy) of the cancer drug Erbitux, in 387 people with metastatic colorectal cancer. Participants will receive either HLX05-N or Erbitux (from the US or EU) along with standard chemotherapy. The study aims to see if HLX05-N works similarly, is safe, and produces a similar immune response. Results could lead to a more affordable treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cetuximab (HLX05-N, a biosimilar to Erbitux) plus chemotherapy (mFOLFOX6)
What this could lead to
If it works, this could provide a more affordable treatment option for metastatic colorectal cancer that is as effective as the current drug Erbitux.
What could go wrong
This is an early Phase 1 trial, so it is mainly checking safety and how the drug behaves in the body. It may not prove that HLX05-N works as well as Erbitux, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••